期刊文献+

多西他赛不同给药方案联合卡培他滨治疗转移性乳腺癌的临床观察 被引量:3

The clinical observation of Docetaxel with weekly and 3 weekly schema combined with Capecitabine for treating metastatic breast cancer
下载PDF
导出
摘要 目的:观察多西他赛不同给药方案联合卡培他滨治疗转移性乳腺癌的疗效和毒副反应。方法:26例转移性乳腺癌患者均接受多西他赛联合卡培他滨方案治疗1,2例多西他赛每周给药剂量为25mg/m2,d18,1,5;卡培他滨1 000mg,2次/d,d1~14。14例多西他赛三周给药剂量为75mg/m2,d1;卡培他滨1000mg,2次/d,d1~14,每3周为1周期。评价两组的有效率及毒副反应。结果:每周组12例患者完全缓解(CR)1例,部分缓解(PR)3例,有效率(CR+PR)33.3%(4/12)。三周组14例患者完全缓解(CR)1例,部分缓解(PR)4例,有效率(CR+PR)35.7%(5/14)。三周组的III~IV度血液学毒性及胃肠道反应均较每周组高,而三周组的周围神经炎较每周组低。结论:多西他赛联合卡培他滨是治疗转移性乳腺癌的有效方案之一,不同给药方案耐受性不同。 Objective:To compare the efficacy and toxicity of Docetaxel with weekly and 3 weekly schema combined with Capecitabine for treating metastatic breast cancer.Methods:26 patients of metastatic breast cancer were given Docetaxel and Capecitabine,12 of them with weekly Docetaxel,about 25mg/m 2,d1.8.15,14 of them with 3 weekly Docetaxel,about 75mg/m 2,d1,both of them were given 1 000mg Capecitabine,twice a day for 14 days.Three weeks called one cycle.Efficacy and toxicity were evaluated.Results:In weekly group 1 patient achieved CR,3 patients achieved PR.The response rate(RR)was 33.3%,while in 3 weekly group 1 patient achieved CR,4 patients achieved PR.The response rate(RR) was 35.7%.The Ⅲ-Ⅳ grade hematologic toxicity and adverse reaction of gastrointestinal tract in 3 weekly group were higner than weekly group.While the peripheral neuritis in 3 weekly group were lower than weekly group.Conclusion:Docetaxel with Capecitabine was one of the available schemas for treating metastatic breast cancer.Differient dosage of docetaxel will achieve differient tolerance for different patients.
出处 《中国民康医学》 2011年第6期658-659,667,共3页 Medical Journal of Chinese People’s Health
关键词 多西他赛 卡培他滨 转移性乳腺癌 Docetaxel Capecitabine Metastatic breast cancer
  • 相关文献

参考文献11

二级参考文献31

  • 1[1]Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efiicacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res, 1998, 4 (4) :1013 被引量:1
  • 2[2]Tsuchida Y, Therasse P. Response evaluation criteria in solid tumors (RECIST): New guidelines. Med Pediatr Oncol, 2001,37 (1) :1 被引量:1
  • 3[4]Jones S, Erban J, Overmoyer B, et al. Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. The 26th Annual SanAntonio Breast Cancer Symposium,2003 (abstract 10) 被引量:1
  • 4[6]Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol, 2000, 45(4):291 被引量:1
  • 5[8]George W Sledge, Donna Neuberg, Patricia Bemardo, et al.Phase Ⅲ trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front- line chemotherapy for metastatic breast cancer: An Intergroup Trial (El193). J Clin Oncol, 2003, 21 (4) :588 被引量:1
  • 6[9]Alba E, Martin M, Ramos M, et al. Multicenter phase randomized trial comparing sequential versus concomitant administration of doxorubicin (A) and docetaxel (T) as first- line treatment of metastatic breast cancer (MBC). GEICAM 9903 Study.ASCO, 2003, 22: 8 (abstract 27) 被引量:1
  • 7[10]O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer:Phase Ⅲ trial results. J Clin Oncol, 2002, 20 (12) :2812 被引量:1
  • 8[11]London Susan Mayor. NICE recommends new treatment for breast and bowel cancer. BMJ, 2003, 326:1166 被引量:1
  • 9[12]Jiang Z, Liu F, Song S, et al. HER-2 overexpression predicts better reponse to taxane chemotherapy in patients with advanced breast cancer. Breast Cancer Research and Treatment,2003, Vol 82 (Suppl), S72. The 26th Annual SanAntonio Breast Cancer Symposium 2003 (abstract 312) 被引量:1
  • 10孙燕 周际昌.临床肿瘤内科手册(第 3版)[M].北京:人民卫生出版社,1966.381. 被引量:1

共引文献132

同被引文献19

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部